Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (November 2023)
25 slides from Island Pharmaceuticals's investor presentation, Nov 6, 2023
Slide 1: Island Pharmaceuticals releases updated investor presentation
6 November 2023 ASX Announcement Island Pharmaceuticals releases updated investor presentation MELBOURNE Australia, 6 November 2023: Australian antiviral drug development company, For personal use only Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to release a copy of an
Slide 2: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) | November 2023 ISLAND PHARMACEUTICALS 1 NOVEMBER 2023
Slide 3: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Island Pharmaceuticals). "estimate", "intend", "believe", "guidance"
Slide 4: Drug repurposing company focused on antiviral therapeutics
For personal use only Island Pharmaceuticals (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS 3 NOVEMBER 2023
Slide 5: Island at a Glance
ISLAND AT A GLANCE For personal use only Dengue infects up to Major market Advancing Single 400m per year* potential Ascending Dose study Now endemic in more than 100 Mosquito-borne diseases, Measure of blood concentration of countries with no current exacerbated by climate change. ISLA-101, followi
Slide 6: WHO quote on dengue infections
For personal use only “About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 17 March 2023 ISLAND PHARMACEUTICALS 5 NOVEMBER 2023
Slide 7: Dengue Is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE For personal use only Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands HealthMap: recent reports of local or imported dengue cases https://www.healthmap.org/dengue/en - visited September 4, 2
Slide 8: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.
Slide 9: WHO quote on dengue threat
For personal use only “Dengue fever will become a major threat in the southern US, southern Europe and new parts of Africa this decade” World Health Organisation, 6 October 2023 ISLAND PHARMACEUTICALS 8 NOVEMBER 2023
Slide 10: Commercial Opportunity
COMMERCIAL OPPORTUNITY For personal use only ISLA-101 has potential as both a prophylactic and therapeutic Travelers Military National Outbreaks The malaria market, expected Partnering with army (CRADA Millions of patients in Latin to reach US$1B by 20261, is in place) for Phase 2a clinical America
Slide 11: Introducing ISLA-101
For personal use only Introducing ISLA-101 ISLAND PHARMACEUTICALS 10 NOVEMBER 2023
Slide 12: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4 demonstrated broad anti-viral activity • In animal models, ISLA-101 is pr
Slide 13: Prevents Animal Deaths from Lethal Dengue
PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE For personal use only ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISL
Slide 14: Recent ISLA-101 Progress
RECENT ISLA-101 PROGRESS For personal use only Announced new patent coverage and two key contracts to support the Single Grant research Ascending Dose support announced study for the planned ILA receives FDA PEACH study in go-ahead for dengue fever ISLA-101 ILA submits program; clinical responses to
Slide 15: Single Ascending Dose Study – Key Activities
SINGLE ASCENDING DOSE STUDY – KEY ACTIVITIES For personal use only Several workstreams are underway, providing support for commencing the Single Ascending Dose study Finalizing shipping Signed Signed Finalize / sign Obtain Human First subject Last subject Final SAD labelling with Clinical Site in Cl
Slide 16: Single Ascending Dose Study Protocol
SINGLE ASCENDING DOSE STUDY PROTOCOL For personal use only The aim of the study is to ensure that administered doses which increase over time could safely achieve blood concentrations of ISLA-101 that are predicated to be effective against the dengue virus. Inclusion Exclusion Dosing • Doses are 300
Slide 17: Study Partners
STUDY PARTNERS For personal use only Scientia Clinical Research is an FDA Beyond is a leading Contract Research audited, early phase clinical trials Organisation (CRO) based in Brisbane, facility, with world-class clinical trial Australia, with a focus on product expertise and state of the art facil
Slide 18: ISLA-101 Development Milestones
ISLA-101 DEVELOPMENT MILESTONES For personal use only • Island expects to have final data from the Single Ascending Dose study for ISLA-101 in early CY2024 • The company plans to seek a meeting with the US FDA to discuss the study outcomes and strategies for how to maximise the data obtained from th
Slide 19: Phase II Dengue (PEACH) Trial Study
PHASE II DENGUE (PEACH) TRIAL STUDY For personal use only “PEACH" study- A Phase 2a, Randomized, Double blind, Placebo-controlled Study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model Phase II trial protocol Administer ISLA-101 daily Up to 4 cohorts/4 arms Inclusion Prim
Slide 20: Building Our Pipeline
BUILDING OUR PIPELINE For personal use only • In addition to ISLA-101, Island is exploring the acquisition or in-licensing of new drug candidates • Specific screening and scoring criteria being applied, based in part on the following criteria: • small molecule program • anti-viral • eligible for a P
Slide 21: Board and Corporate Snapshot
BOARD AND CORPORATE SNAPSHOT For personal use only Dr Paul MacLeman Dr David Foster Dr David Brookes Mr Albert Hansen Dr Anna Lavelle Corporate snapshot Executive Chairman Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Key data points Dr Paul MacLeman brings D
Slide 22: Other Key Team Members
OTHER KEY TEAM MEMBERS For personal use only Bobbi Drais Teresa Byrne Senior Regulatory Consultant Vice President Clinical Product Development Bobbi is a dynamic global leader with an impressive track Teresa is an experienced Clinical Research Executive, with record spanning over 25 years in regulat
Slide 23: Scientific Advisory
SCIENTIFIC ADVISORY SLIDE For personal use only Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the Professor Stephen Thomas, MD has an international Amy Patick is a scientific consultant with deep biotechnology and pharmaceutical industry and is leadersh
Slide 24: Upcoming Milestones
UPCOMING MILESTONES For personal use only Completed H1 FY 2024 (Jul – Dec 2023) H2 FY 2024 (Jan – Jun 2024) Investigational New Drug • Key US and Australian patents • Dose final Single Ascending application for ISLA-101 granted for ISLA-101 Dose study subject PEACH study opens • Obtain HREC (i.e. IR
Slide 25: Contact
For personal use only Contact David Foster Chief Executive Officer & Executive Director dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 24 NOVEMBER 2023
Island Pharmaceuticals — Investor Presentation (November 2023) on 6ix